电话:
+86 (0512) 65829739
传真:
+86 (010) 6788 5057
电子邮件:
orders@antibodies-online.cn

Recombinant EGFR (Nimotuzumab Biosimilar) 抗体

This Humanized 单克隆 antibody specifically detects EGFR (Nimotuzumab Biosimilar) in FACS 和 in vivo. It exhibits reactivity toward 人.
产品编号 ABIN7795094
发货至: 中国
Contact our Customer Service for availability and price in your country. Contact Info

Our Local Distributor

中国
北京 101111
No. 88 KeChuang 6th Street
Beijing Economic Technological Development Area
Room 801-803
4A Biotech Co.,Ltd.
Tel +86 (0512) 65829739 传真 +86 (010) 6788 5057

Quick Overview for Recombinant EGFR (Nimotuzumab Biosimilar) 抗体 (ABIN7795094)

抗原

EGFR (Nimotuzumab Biosimilar)

抗体类型

Recombinant Antibody

适用

宿主

  • 1
  • 1
  • 1
  • 1
  • 1
Humanized

克隆类型

  • 3
  • 2
单克隆

标记

  • 5
This EGFR (Nimotuzumab Biosimilar) antibody is un-conjugated

应用范围

  • 3
  • 3
  • 3
  • 1
Flow Cytometry (FACS), In vivo Studies (in vivo)

质量等级

Research Grade
  • Expression System

    Mammalian cells

    原理

    Nimotuzumab Biosimilar, EGFR Monoclonal Antibody

    产品特性

    Nimotuzumab Biosimilar uses the same protein sequences as the therapeutic antibody nimotuzumab. Like cetuximab, nimotuzumab is a humanized monoclonal antibody that binds to the epidermal growth factor receptor (EGFR), a signalling protein that normally controls cell division. In some cancers, this receptor is altered to cause uncontrolled cell division, a hallmark of cancer. These monoclonal antibodies block EGFR and stop the uncontrolled cell division. It has a humanized human-mouse h-R3 heavy chain and a humanized human-mouse h-R3 κ-chain. Nimotuzumab binds with optimal affinity and high specificity to the extracellular region of EGFR (epidermal growth factor receptor). This results in a blockade of ligand binding and receptor activation. Epidermal growth factor receptor (EGFR) is a key target in the development of cancer therapeutics. EGFR-targeting drugs have been shown to improve response when used with conventional treatments such as radiation therapy and chemotherapy.

    纯化方法

    Protein A or G affinity column

    纯度

    >95 % by reducing SDS-PAGE

    内毒素水平

    < 1 EU per 1 mg of the protein by the LAL method

    免疫原

    Human EGFR / ErbB-1
  • 应用备注

    Optimal working dilution should be determined by the investigator.

    限制

    仅限研究用
  • 状态

    Liquid

    浓度

    > 3 mg/mL

    储存条件

    4 °C,-20 °C

    储存方法

    Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.
  • 抗原

    EGFR (Nimotuzumab Biosimilar)

    别名

    Nimotuzumab Biosimilar

    物质类

    Biosimilar
You are here: